NAMS
NewAmsterdam Pharma·NASDAQ
--
--(--)
--
--(--)
2.53 / 10
Underperform
Fundamental assessment shows significant weaknesses: declining revenues (Total Operating Revenue YoY -31.47%, Operating Revenue YoY -31.47%) and high Days Sales Outstanding (72.55) indicate operational inefficiencies. Although the Interest Coverage Ratio (15.48) is acceptable, other metrics like PB-ROE (2.92) and Asset-MV are suboptimal, leading to an overall 'Underperform' rating with a 2.5/10 score.
Analysis Checks(7/10)
Revenue-MV
Value-6.97
Score1/3
Weight10.10%
1M Return4.24%
Value-6.97
Score1/3
Weight10.10%
1M Return4.24%
Days sales outstanding
Value72.55
Score1/3
Weight-2.76%
1M Return-1.57%
Value72.55
Score1/3
Weight-2.76%
1M Return-1.57%
Net income-Revenue
Value-0.17
Score2/3
Weight20.08%
1M Return8.45%
Value-0.17
Score2/3
Weight20.08%
1M Return8.45%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-2.01%
1M Return-1.11%
Value15.48
Score2/3
Weight-2.01%
1M Return-1.11%
Asset-MV
Value-0.50
Score2/3
Weight25.86%
1M Return10.15%
Value-0.50
Score2/3
Weight25.86%
1M Return10.15%
Total operating revenue (YoY growth rate %)
Value-31.47
Score2/3
Weight2.15%
1M Return1.11%
Value-31.47
Score2/3
Weight2.15%
1M Return1.11%
Profit-MV
Value0.46
Score2/3
Weight20.06%
1M Return8.45%
Value0.46
Score2/3
Weight20.06%
1M Return8.45%
PB-ROE
Value2.92
Score0/3
Weight5.99%
1M Return2.72%
Value2.92
Score0/3
Weight5.99%
1M Return2.72%
Operating revenue (YoY growth rate %)
Value-31.47
Score2/3
Weight0.83%
1M Return0.43%
Value-31.47
Score2/3
Weight0.83%
1M Return0.43%
Cash-MV
Value-0.07
Score2/3
Weight19.72%
1M Return8.41%
Value-0.07
Score2/3
Weight19.72%
1M Return8.41%
Revenue-MV
Value-6.97
Score1/3
Weight10.10%
1M Return4.24%
Value-6.97
Score1/3
Weight10.10%
1M Return4.24%
Total operating revenue (YoY growth rate %)
Value-31.47
Score2/3
Weight2.15%
1M Return1.11%
Value-31.47
Score2/3
Weight2.15%
1M Return1.11%
Days sales outstanding
Value72.55
Score1/3
Weight-2.76%
1M Return-1.57%
Value72.55
Score1/3
Weight-2.76%
1M Return-1.57%
Profit-MV
Value0.46
Score2/3
Weight20.06%
1M Return8.45%
Value0.46
Score2/3
Weight20.06%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight20.08%
1M Return8.45%
Value-0.17
Score2/3
Weight20.08%
1M Return8.45%
PB-ROE
Value2.92
Score0/3
Weight5.99%
1M Return2.72%
Value2.92
Score0/3
Weight5.99%
1M Return2.72%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-2.01%
1M Return-1.11%
Value15.48
Score2/3
Weight-2.01%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value-31.47
Score2/3
Weight0.83%
1M Return0.43%
Value-31.47
Score2/3
Weight0.83%
1M Return0.43%
Asset-MV
Value-0.50
Score2/3
Weight25.86%
1M Return10.15%
Value-0.50
Score2/3
Weight25.86%
1M Return10.15%
Cash-MV
Value-0.07
Score2/3
Weight19.72%
1M Return8.41%
Value-0.07
Score2/3
Weight19.72%
1M Return8.41%
Is NAMS undervalued or overvalued?
- NAMS scores 2.53/10 on fundamentals and holds a Premium valuation at present. Backed by its -17.35% ROE, -627.28% net margin, -23.47 P/E ratio, 5.34 P/B ratio, and 7.69% earnings growth, these metrics solidify its Underperform investment rating.
